Literature DB >> 10372857

Waxing and waning gynecomastia: an indication of noncompliant use of prescribed medication.

J A Miller1, B Pramanik, P Gilhooly.   

Abstract

We present two cases of recurrent gynecomastia in men enrolled in a placebo-controlled trial evaluating the efficacy of finasteride in treating benign prostatic hyperplasia. When the pharmacologic records were examined, it was apparent that the breast tissue hyperplasia diminished when the patients become noncompliant with their study medication and then resumed therapy. Because of the difficulty in obtaining accurate data on an individual's ability to maintain a consistent pharmacologic regimen, we believe that observing such "waxing and waning gynecomastia" may provide the physician with a clue regarding a patient's actual compliance with certain medications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372857

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

1.  Finasteride induced Gynecomastia: Case report and Review of the Literature.

Authors:  Yuval Ramot; Tali Czarnowicki; Abraham Zlotogorski
Journal:  Int J Trichology       Date:  2009-01

Review 2.  Gynecomastia and drugs: a critical evaluation of the literature.

Authors:  Frank Q Nuttall; Rohit S Warrier; Mary C Gannon
Journal:  Eur J Clin Pharmacol       Date:  2015-04-02       Impact factor: 2.953

3.  Influence of Postoperative Finasteride Therapy on Recurrence of Gynecomastia After Mastectomy in Men Taking Finasteride for Alopecia.

Authors:  Seung Geun Lee; Pyoung Jae Park; Sung Ryul Lee; Bum Hwan Koo; Geon Young Byun; Myoung Jin Kim; Hyok Jo Kang; Sarang Kim; Beom Seok Oh; Young Hyun Lee
Journal:  Am J Mens Health       Date:  2019 Sep-Oct

4.  The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).

Authors:  Olulade Ayodele; Howard J Cabral; David McManus; Susan Jick
Journal:  Clin Epidemiol       Date:  2021-08-03       Impact factor: 4.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.